CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 29 enrolled
Drug / intervention
LIK066 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03152591
NCT03152591Phase 2Completed
CompareCT.gov

A Randomized, Subject- and Investigator-blinded, Placebo-controlled Pharmacodynamic Study of Oral LIK066 in Overweight and Obese Women With Polycystic Ovary Syndrome

Novartis Pharmaceuticals·interventional·Posted May 15, 2017·Updated Jan 5, 2021

In Brief

A Phase 2 clinical trial evaluating LIK066 and Placebo for Polycystic Ovary Syndrome. Completed, enrolled 29 participants across 5 sites in 2 countries.

Detailed Summary

The purpose of the study was to evaluate whether LIK066 can be developed for the treatment of polycystic ovary syndrome (PCOS) in overweight and obese women.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPolycystic Ovary Syndrome
CountriesGermany, United States
Collaborators--

Timeline

Phase 2CompletedFinished
201820192020202120222023202420252026
First PostedMay 15, 2017
Enrollment StartJul 24, 2017
Primary CompletionJun 25, 2018
TodayJul 2, 2026
Enrollment to primary: 11 monthsPosted 9.1 years ago

Interventions

LIK066drug

LIK066 tablets for oral administration

Placebodrug

Placebo tablets matching LIK066 tablets, for oral administration